{
    "pmcid": "PMC5712579",
    "title": "Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population",
    "study_parameters": {
        "summary": "This study investigated the association of HLA-A and HLA-B alleles with lamotrigine-induced cutaneous adverse drug reactions (CADR) in Thai patients. It was a case-control study involving 15 patients with CADR and 50 lamotrigine-tolerant controls. The study found significant associations between certain HLA alleles and CADR, suggesting potential genetic markers for screening.",
        "study_type": {
            "content": "case-control, retrospective",
            "explanation": "The study compares individuals with a condition (CADR) to those without (tolerant controls) to identify associated factors, which is characteristic of a case-control study. It uses existing records to look backward at exposures and outcomes, indicating a retrospective design.",
            "quotes": [
                "A case\u2013control study was performed at the Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Thailand."
            ]
        },
        "participant_info": {
            "content": "The study included 15 patients with lamotrigine-induced CADR (10 cases with MPE, 4 cases with SJS, and 1 case with DRESS) and 50 lamotrigine-tolerant controls. The mean age of the CADR patients was 35.2 years, and 73.3% were female. The participants were Thai, and the study was conducted in Thailand.",
            "explanation": "The participant information includes age, gender, and ethnicity details, as well as the breakdown of the study groups (CADR patients and tolerant controls).",
            "quotes": [
                "DNA samples from 15 LTG-induced CADR patients (10 cases with MPE, 4 cases with SJS, and 1 case with DRESS) and 50 LTG-tolerant controls and the general population group were genotyped.",
                "The mean age of the LTG-induced CADR patients was 35.2 \u00b1 22.1 and 73.3% were female."
            ]
        },
        "study_design": {
            "content": "The study was conducted at the Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center, Ramathibodi Hospital, Thailand. It involved 15 patients with lamotrigine-induced CADR and 50 lamotrigine-tolerant controls. HLA-A and HLA-B genotyping was performed using PCR-SSO.",
            "explanation": "The study design description includes the study population, sample size, and the method used for genotyping, which are key elements of the study design.",
            "quotes": [
                "A case\u2013control study was performed at the Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Thailand.",
                "Fifteen patients with LTG-induced CADR [10 MPE; 4 Stevens\u2013Johnson syndrome; and 1 drug reaction with eosinophilia and systemic symptoms] and 50 LTG-tolerant controls were included in the study.",
                "HLA-A and HLA-B genotyping was performed using polymerase chain reaction-sequence-specific oligonucleotides probes."
            ]
        },
        "study_results": {
            "content": "The study found that the HLA-A*02:07 and HLA-B*15:02 alleles were significantly associated with lamotrigine-induced CADR in Thai patients, with odds ratios of 7.83 (95% CI: 1.60\u201338.25, P = 0.013) and 4.89 (95% CI: 1.28\u201318.67, P = 0.014), respectively. HLA-A*33:03, HLA-B*15:02, and HLA-B*44:03 were associated with LTG-induced MPE.",
            "explanation": "The study results include the main findings, odds ratios, and p-values, which are critical for understanding the significance of the associations found.",
            "quotes": [
                "The proportion of HLA-A\u221702:07 and HLA-B\u221715:02 allele carriers were significantly higher in the LTG-induced CADR group than in the tolerant controls [odds ratio (OR): 7.83; 95% confidence interval (CI): 1.60\u201338.25; P = 0.013, and OR: 4.89; 95% CI: 1.28\u201318.67; P = 0.014].",
                "In addition, subjects with HLA-A\u221733:03, HLA-B\u221715:02, and HLA-B\u221744:03 were significantly higher in the LTG-induced MPE group than in the tolerant controls (OR: 8.27; 95% CI: 1.83\u201337.41; P = 0.005, OR: 7.33; 95% CI: 1.63\u201333.02; P = 0.005; and OR: 10.29; 95% CI: 1.45\u201372.81; P = 0.029)."
            ]
        },
        "allele_frequency": {
            "content": "The HLA-B*15:02 allele was found in 40.0% of patients who developed CADR and in 12.0% of the tolerant patients. HLA-A*02:07 was present in 33.3% of LTG-induced CADR patients.",
            "explanation": "The allele frequency information includes the frequency of the HLA alleles in the CADR patients and the tolerant controls, which is relevant for understanding the genetic predisposition.",
            "quotes": [
                "We found the HLA-B\u221715:02 allele in 40.0% of patients who developed CADR and in 12.0% of the tolerant patients.",
                "Compared with the HLA-B allele, HLA-A\u221702:07 was present in 33.3% of LTG-induced CADR patients."
            ]
        },
        "additional_resource_links": [
            "https://www.frontiersin.org/articles/10.3389/fphar.2017.00879/full#supplementary-material"
        ]
    },
    "annotations": {
        "relationships": [
            {
                "gene": "HLA-A",
                "polymorphism": "HLA-A*02:07",
                "relationship_effect": "HLA-A*02:07 is associated with increased risk of lamotrigine-induced cutaneous adverse drug reactions (CADR) in the Thai population.",
                "p_value": "0.013",
                "citations": [
                    "# Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population\n\n## Metadata\n**Authors:** Napatrupron Koomdee, Jirawat Pratoomwun, Thawinee Jantararoungtong, Voralaksana Theeramoke, Wichittra Tassaneeyakul, Jettanong Klaewsongkram, Ticha Rerkpattanapipat, Siwalee Santon, Apichaya Puangpetch, Utcharee Intusoma, Therdpong Tempark, Tayard Deesudchit, Patompong Satapornpong, Anannit Visudtibhan, Chonlaphat Sukasem\n**Journal:** Frontiers in Pharmacology\n**Date:** 2017 Nov 29\n**DOI:** [10.3389/fphar.2017.00879](https://doi.org/10.3389/fphar.2017.00879)\n**PMID:** 29238301\n**PMCID:** PMC5712579\n**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712579/\n**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf)\n\n## Abstract\n\nBackground: Lamotrigine (LTG) is commonly used for treatment of epilepsy and bipolar disorder.",
                    "HLA-A and HLA-B genotype data of LTG-induced cutaneous adverse drug reaction patients.",
                    "Keywords: lamotrigine, HLA-A, HLA-B, cutaneous adverse drug reactions, Thai population\n\n**Keywords:**Keywords: lamotrigine, *HLA-A*HLA-A, *HLA-B*HLA-B, cutaneous adverse drug reactions, Thai population\n\n## Introduction\n\nLamotrigine (LTG) is a phenyltriazine derivative which is used in the treatment of epilepsy and bipolar disorder."
                ]
            },
            {
                "gene": "HLA-B",
                "polymorphism": "HLA-B*15:02",
                "relationship_effect": "HLA-B*15:02 is associated with increased risk of lamotrigine-induced cutaneous adverse drug reactions (CADR) in the Thai population.",
                "p_value": "0.014",
                "citations": [
                    "Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B\u22171502 in a Han Chinese population.",
                    "Association between HLA-B\u22171502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population.",
                    "# Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population\n\n## Metadata\n**Authors:** Napatrupron Koomdee, Jirawat Pratoomwun, Thawinee Jantararoungtong, Voralaksana Theeramoke, Wichittra Tassaneeyakul, Jettanong Klaewsongkram, Ticha Rerkpattanapipat, Siwalee Santon, Apichaya Puangpetch, Utcharee Intusoma, Therdpong Tempark, Tayard Deesudchit, Patompong Satapornpong, Anannit Visudtibhan, Chonlaphat Sukasem\n**Journal:** Frontiers in Pharmacology\n**Date:** 2017 Nov 29\n**DOI:** [10.3389/fphar.2017.00879](https://doi.org/10.3389/fphar.2017.00879)\n**PMID:** 29238301\n**PMCID:** PMC5712579\n**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712579/\n**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf)\n\n## Abstract\n\nBackground: Lamotrigine (LTG) is commonly used for treatment of epilepsy and bipolar disorder."
                ]
            },
            {
                "gene": "HLA-A",
                "polymorphism": "HLA-A*33:03",
                "relationship_effect": "HLA-A*33:03 is associated with increased risk of lamotrigine-induced maculopapular exanthema (MPE) in the Thai population.",
                "p_value": "0.005",
                "citations": [
                    "# Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population\n\n## Metadata\n**Authors:** Napatrupron Koomdee, Jirawat Pratoomwun, Thawinee Jantararoungtong, Voralaksana Theeramoke, Wichittra Tassaneeyakul, Jettanong Klaewsongkram, Ticha Rerkpattanapipat, Siwalee Santon, Apichaya Puangpetch, Utcharee Intusoma, Therdpong Tempark, Tayard Deesudchit, Patompong Satapornpong, Anannit Visudtibhan, Chonlaphat Sukasem\n**Journal:** Frontiers in Pharmacology\n**Date:** 2017 Nov 29\n**DOI:** [10.3389/fphar.2017.00879](https://doi.org/10.3389/fphar.2017.00879)\n**PMID:** 29238301\n**PMCID:** PMC5712579\n**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712579/\n**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf)\n\n## Abstract\n\nBackground: Lamotrigine (LTG) is commonly used for treatment of epilepsy and bipolar disorder.",
                    "Keywords: lamotrigine, HLA-A, HLA-B, cutaneous adverse drug reactions, Thai population\n\n**Keywords:**Keywords: lamotrigine, *HLA-A*HLA-A, *HLA-B*HLA-B, cutaneous adverse drug reactions, Thai population\n\n## Introduction\n\nLamotrigine (LTG) is a phenyltriazine derivative which is used in the treatment of epilepsy and bipolar disorder.",
                    "The PCR products were then hybridized against a panel of oligonucleotide probes on coated polystyrene microspheres that had sequences complementary to stretches of polymorphisms within the target *HLA-A*HLA-A, *B*B alleles (a LABType^\u00ae^\u00aeSSO, One Lambda Inc."
                ]
            },
            {
                "gene": "HLA-B",
                "polymorphism": "HLA-B*15:02",
                "relationship_effect": "HLA-B*15:02 is associated with increased risk of lamotrigine-induced maculopapular exanthema (MPE) in the Thai population.",
                "p_value": "0.005",
                "citations": [
                    "Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B\u22171502 in a Han Chinese population.",
                    "# Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population\n\n## Metadata\n**Authors:** Napatrupron Koomdee, Jirawat Pratoomwun, Thawinee Jantararoungtong, Voralaksana Theeramoke, Wichittra Tassaneeyakul, Jettanong Klaewsongkram, Ticha Rerkpattanapipat, Siwalee Santon, Apichaya Puangpetch, Utcharee Intusoma, Therdpong Tempark, Tayard Deesudchit, Patompong Satapornpong, Anannit Visudtibhan, Chonlaphat Sukasem\n**Journal:** Frontiers in Pharmacology\n**Date:** 2017 Nov 29\n**DOI:** [10.3389/fphar.2017.00879](https://doi.org/10.3389/fphar.2017.00879)\n**PMID:** 29238301\n**PMCID:** PMC5712579\n**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712579/\n**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf)\n\n## Abstract\n\nBackground: Lamotrigine (LTG) is commonly used for treatment of epilepsy and bipolar disorder.",
                    "10.1016/j.eplepsyres.2010.10.006  [DOI](https://doi.org/10.1016/j.eplepsyres.2010.10.006) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21071176/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Epilepsy%20Res.&title=Association%20study%20of%20lamotrigine-induced%20cutaneous%20adverse%20reactions%20and%20HLA-B%E2%88%971502%20in%20a%20Han%20Chinese%20population.&author=D.%20M.%20An&author=X.%20T.%20Wu&author=F.%20Y.%20Hu&author=B.%20Yan&author=H.%20Stefan&volume=92&publication_year=2010&pages=226-230&pmid=21071176&doi=10.1016/j.eplepsyres.2010.10.006&)\n\n3."
                ]
            },
            {
                "gene": "HLA-B",
                "polymorphism": "HLA-B*44:03",
                "relationship_effect": "HLA-B*44:03 is associated with increased risk of lamotrigine-induced maculopapular exanthema (MPE) in the Thai population.",
                "p_value": "0.029",
                "citations": [
                    "Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B\u22171502 in a Han Chinese population.",
                    "# Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population\n\n## Metadata\n**Authors:** Napatrupron Koomdee, Jirawat Pratoomwun, Thawinee Jantararoungtong, Voralaksana Theeramoke, Wichittra Tassaneeyakul, Jettanong Klaewsongkram, Ticha Rerkpattanapipat, Siwalee Santon, Apichaya Puangpetch, Utcharee Intusoma, Therdpong Tempark, Tayard Deesudchit, Patompong Satapornpong, Anannit Visudtibhan, Chonlaphat Sukasem\n**Journal:** Frontiers in Pharmacology\n**Date:** 2017 Nov 29\n**DOI:** [10.3389/fphar.2017.00879](https://doi.org/10.3389/fphar.2017.00879)\n**PMID:** 29238301\n**PMCID:** PMC5712579\n**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712579/\n**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf)\n\n## Abstract\n\nBackground: Lamotrigine (LTG) is commonly used for treatment of epilepsy and bipolar disorder.",
                    "10.1016/j.eplepsyres.2010.10.006  [DOI](https://doi.org/10.1016/j.eplepsyres.2010.10.006) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21071176/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Epilepsy%20Res.&title=Association%20study%20of%20lamotrigine-induced%20cutaneous%20adverse%20reactions%20and%20HLA-B%E2%88%971502%20in%20a%20Han%20Chinese%20population.&author=D.%20M.%20An&author=X.%20T.%20Wu&author=F.%20Y.%20Hu&author=B.%20Yan&author=H.%20Stefan&volume=92&publication_year=2010&pages=226-230&pmid=21071176&doi=10.1016/j.eplepsyres.2010.10.006&)\n\n3."
                ]
            },
            {
                "gene": "HLA-B",
                "polymorphism": "HLA-B*35:08",
                "relationship_effect": "HLA-B*35:08 is associated with increased risk of lamotrigine-induced cutaneous adverse drug reactions (CADR) in the Thai population (compared to general population, but rare allele).",
                "p_value": "0.030",
                "citations": [
                    "# Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population\n\n## Metadata\n**Authors:** Napatrupron Koomdee, Jirawat Pratoomwun, Thawinee Jantararoungtong, Voralaksana Theeramoke, Wichittra Tassaneeyakul, Jettanong Klaewsongkram, Ticha Rerkpattanapipat, Siwalee Santon, Apichaya Puangpetch, Utcharee Intusoma, Therdpong Tempark, Tayard Deesudchit, Patompong Satapornpong, Anannit Visudtibhan, Chonlaphat Sukasem\n**Journal:** Frontiers in Pharmacology\n**Date:** 2017 Nov 29\n**DOI:** [10.3389/fphar.2017.00879](https://doi.org/10.3389/fphar.2017.00879)\n**PMID:** 29238301\n**PMCID:** PMC5712579\n**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712579/\n**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf)\n\n## Abstract\n\nBackground: Lamotrigine (LTG) is commonly used for treatment of epilepsy and bipolar disorder.",
                    "Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B\u22171502 in a Han Chinese population.",
                    "10.1016/j.eplepsyres.2010.10.006  [DOI](https://doi.org/10.1016/j.eplepsyres.2010.10.006) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21071176/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Epilepsy%20Res.&title=Association%20study%20of%20lamotrigine-induced%20cutaneous%20adverse%20reactions%20and%20HLA-B%E2%88%971502%20in%20a%20Han%20Chinese%20population.&author=D.%20M.%20An&author=X.%20T.%20Wu&author=F.%20Y.%20Hu&author=B.%20Yan&author=H.%20Stefan&volume=92&publication_year=2010&pages=226-230&pmid=21071176&doi=10.1016/j.eplepsyres.2010.10.006&)\n\n3."
                ]
            },
            {
                "gene": "HLA-B",
                "polymorphism": "HLA-B*39:01",
                "relationship_effect": "HLA-B*39:01 is associated with increased risk of lamotrigine-induced cutaneous adverse drug reactions (CADR) in the Thai population (compared to general population, but rare allele).",
                "p_value": "0.022",
                "citations": [
                    "# Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population\n\n## Metadata\n**Authors:** Napatrupron Koomdee, Jirawat Pratoomwun, Thawinee Jantararoungtong, Voralaksana Theeramoke, Wichittra Tassaneeyakul, Jettanong Klaewsongkram, Ticha Rerkpattanapipat, Siwalee Santon, Apichaya Puangpetch, Utcharee Intusoma, Therdpong Tempark, Tayard Deesudchit, Patompong Satapornpong, Anannit Visudtibhan, Chonlaphat Sukasem\n**Journal:** Frontiers in Pharmacology\n**Date:** 2017 Nov 29\n**DOI:** [10.3389/fphar.2017.00879](https://doi.org/10.3389/fphar.2017.00879)\n**PMID:** 29238301\n**PMCID:** PMC5712579\n**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712579/\n**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC5712579/pdf/fphar-08-00879.pdf)\n\n## Abstract\n\nBackground: Lamotrigine (LTG) is commonly used for treatment of epilepsy and bipolar disorder.",
                    "Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B\u22171502 in a Han Chinese population.",
                    "10.1016/j.eplepsyres.2010.10.006  [DOI](https://doi.org/10.1016/j.eplepsyres.2010.10.006) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21071176/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Epilepsy%20Res.&title=Association%20study%20of%20lamotrigine-induced%20cutaneous%20adverse%20reactions%20and%20HLA-B%E2%88%971502%20in%20a%20Han%20Chinese%20population.&author=D.%20M.%20An&author=X.%20T.%20Wu&author=F.%20Y.%20Hu&author=B.%20Yan&author=H.%20Stefan&volume=92&publication_year=2010&pages=226-230&pmid=21071176&doi=10.1016/j.eplepsyres.2010.10.006&)\n\n3."
                ]
            }
        ]
    }
}